The Importance of Clinical Research Trials
Studies Currently Recruiting
DO YOU HAVE ASTHMA? Volunteers, ages 18 to 65, are invited to participate in an asthma study to compare different doses of an inhaled corticosteroid medication. Compensation available.
RESEARCH STUDY: Individuals at least 18 years of age who have previously been diagnosed with moderate to severe asthma and have a history of persistent symptoms or uncontrolled asthma while using an inhaled corticosteroid (with or without a long acting beta-agonist) are invited to participate in this study to characterize the relationships between the levels of peripheral blood biomarkers (IgE and eosinophils) and airway expression of certain genes (IL-13 and others). The study hopes to characterize relationships for use in future therapeutic trials and potentially identify new molecular targets for future treatment. The study lasts between 17 and 28 days. Qualified participants receive measurements to evaluate lung function, asthma questionnaires and assessment, and a bronchoscopy.Compensation is provided. For more information, e-mail harold.winnike@uiowa.edu or call 319-356-3240 or 877-428-0635
Active Studies, Not Recruiting
EFFECTIVENESS OF A NEW ASTHMA MEDICATION: Individuals at least 12 years of age who have a history of persistent allergic asthma for at least one year and are currently use some form of medication to treat their asthma are invited to participate in this study to evaluate the anti-inflammatory effects of low, medium, and high doses of a combination of an inhaled corticosteroid and long acting bronchodilator (long acting beta-agonist) as compared to placebo. For more information, e-mail harold.winnike@uiowa.edu or call 319- 356-3240 or 877-428-0635.
EXCELS: Evaluating the safety of Xolair in clinical practice when used in combination with standard asthma regimens in people with moderate to sever, persistent asthma. Immunoglobulin E (IgE) is a natural protein present in the human body that has been shown to play an important part in allergic reaction and the rush of events that result in allergic asthma. Xolair is designed to bind to the IgE in the body and prevent if from starting asthmatic reactions. As part of routine follow-up for newly approved drugs, the study will follow patients on Xolair and off Xolair for a five-year period to evaluate the safety of the drug over a longer period of time.
EXTRA: Assess the effectiveness of Xolair in subjects with moderate to severe asthma who still have symptoms despite treatment with high-dose ICS + LABA twice daily.
|
